News

Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at

PROVENGE (sipuleucel-T) was the first U.S. Food and Drug Administration (FDA)-approved immunotherapy made from a patient’s own immune cells. “We are pleased to work with Dendreon on this

The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced

The artificial intelligence software, created by researchers at Imperial College London and the University of Melbourne, has been able to predict the prognosis of patients with ovarian cancer

Vitrakvi and BAY 2731954 are oncology compounds, which are being developed for the treatment of advanced solid tumors harboring NTRK gene fusions in adult and pediatric patient population.

In the complete response letter (CRL) it issued to the company, the FDA said that it cannot approve the New Drug Application (NDA) of iclaprim in its present

Cenobamate is a novel and small molecule investigational antiepileptic drug being developed to treat partial-onset seizures in adult patients. Under exclusive licensing agreement, Arvelle will develop and commercialize

Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech

CAROLINA is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor. The trial evaluated the cardiovascular safety of Tradjenta (5 mg once daily) compared with